Regeneron Pharmaceuticals (REGN)
$611.11 1.24 (0.20%)
15:37 EDT REGN Stock Quote Delayed 30 Minutes
Previous Close $612.35
Market Cap 64.75B
PE Ratio 49.52
Volume (Avg. Vol.) 279,246
Day's Range 607.27 - 616.23
52-Week Range 271.37 - 664.64
Dividend & Yield N/A (N/A)
REGN Stock Predictions, Articles, and Regeneron Pharmaceuticals News
- From InvestorPlace
- From the Web
The SPY and QQQ were our focus, while Microsoft and Regeneron were our other top stock trades for Tuesday.
With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.
Thursday's big stock charts detail the hopes for 3 stocks trying to recover from multi-year lows.
Regeneron Pharmaceuticals (REGN) earnings for the biotechnology company's third quarter of 2019 have REGN stock soaring on Tuesday.
Cara stock is up ahead of its presentations at Kidney Week 2019. Unless it reports bad news, Cara Therapeutics looks ready to run.
Of the undervalued stocks that Goldman Sachs recently thrust into the spotlight, these three are the most promising stocks to buy. Here's what you need to know about each.
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Biotech stocks have been looking rough lately, and these four names have been helping to lead the charge lower.
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
This morning, I am recommending a bullish trade on Repligen Corporation (NASDAQ:RGEN), the bioprocessing company.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
Regeneron Pharmaceuticals earnings for the first quarter of 2019 have REGN stock falling on Tuesday due to poor results for the period.
Biotech stocks fell sharply in the last few weeks, mostly on no new news. This drop may have created an entry point for investors.
While some companies are doing a good job closing their CEO-Worker wage gaps, these seven companies are not.
When drug companies fall out of favor, as now, I look first to companies with a method for drug discovery like Regeneron stock.
From Talk Markets
Navellier RatingsPowered by Portfolio Grader